Barry Coller, MD

Barry Coller, M.D., is Vice President for Medical Affairs at the Rockefeller University in New York as well as the David Rockefeller Professor of Medicine, Head of the Allen and Frances Adler Laboratory of Blood and Vascular Biology, and Physician-in-Chief of the Rockefeller University Hospital.  From 1993-2001 he was the Murray M. Rosenberg Professor of Medicine and Chairman of the Samuel Bronfman Department of Medicine at the Mount Sinai School of Medicine in New York City. Dr. Coller received his B.A. degree, magna cum laude from Columbia College and his M.D. from New York University School of Medicine.  He completed his residency in internal medicine at Bellevue Hospital in New York City and advanced training in hematology and clinical pathology at the National Institutes of Health. He joined the faculty at Stony Brook in 1976 as an Assistant Professor of Medicine in the Division of Hematology.  During his years at Stony Brook he was the Clinical Director and Head of the Hematology Division, and Clinical Chief of the University Hospital Hematology Laboratory. Dr. Coller became Professor of Medicine and Pathology at Stony Brook and was awarded the title of Distinguished Service Professor of Medicine and Pathology 993. Throughout his career, he has focused on medical and scientific education linked to outcome analyses to improve the quality of medical school training.

Dr. Coller is a member of Phi Beta Kappa, Alpha Omega Alpha, the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the National Academy of Sciences. He is a Fellow of the New York Academy of Medicine, the National Academy of Inventors, the American Association for the Advancement of Science, and the American Academy of Arts & Sciences; he is also a Master of the American College of Physicians. Dr. Coller served as President of the American Society of Hematology in 1997-1998, as founding President of the Society for Clinical and Translational Science from 2008-2011, and as a member of the Advisory Council of the National Heart, Lung and Blood Institute from 2008-2012.

Dr. Coller’s research interests have focused on hemostasis and thrombosis, in particular platelet physiology.  He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoPro; Centocor/Eli Lilly) was approved for human use to prevent ischemic complications of percutaneous coronary interventions such as angioplasty and stent insertion by the FDA in 1994. More than 5.0 million patients have been treated with abciximab. He also developed an assay to assess platelet function, and FDA-approved automated derivatives of that assay (VerifyNow; Accumetrics) are used in the U.S. Europe, and countries in Asia. Dr. Coller is the recipient or a co-recipient of twenty-two U.S. patents.

Dr. Coller’s awards include: 1982 John Simon Guggenheim Memorial Foundation Fellow, 1998 Jacobi Medallion, Mount Sinai Alumni Association; 2001 Alexander Richman Award for Humanism in Medicine, Mount Sinai School of Medicine: 2010 Ernest Beutler Lecture and Award, American Society of Hematology; and Honorary degrees from North Shore-LIJ Graduate School of Molecular Medicine, Stony Brook School of Medicine, and Baylor College of Medicine.